Physician profile
Suzanne Shugg
NPI 1811997240
$24,609.57
in general payments reported to CMS, 2019-2025
26 companies · $3,398 in 2025
The $3,398 reported for 2025 was more than what 98% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,002 · 2022: $1,943 · 2023: $8,860 · 2024: $9,407 · 2025: $3,398.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Consulting Fee: $5,855 · Food and Beverage: $4,230 · Travel and Lodging: $1,203 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,313.00 |
| Consulting Fee | $5,855.00 |
| Food and Beverage | $4,230.23 |
| Travel and Lodging | $1,202.53 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $16,833.47 | 2021-2025 | Evkeeza |
| Novartis Pharmaceuticals Corporation | $3,253.72 | 2023-2025 | Leqvio |
| Amgen INC. | $1,447.56 | 2021-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $894.75 | 2021-2025 | Nexletol |
| Novo Nordisk INC | $734.25 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Cvrx, INC. | $236.48 | 2022-2024 | Barostim Neo System |
| Boston Scientific Corporation | $207.03 | 2022-2025 | Cds - Mct/Cem Monitoring, Watchman Flx |
| Amarin Pharma, INC. | $171.03 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $108.62 | 2021-2025 | Verquvo, Capvaxive |
| Althera Pharmaceuticals LLC | $93.62 | 2021-2022 | |
| Lilly USA, LLC | $75.31 | 2025 | Zepbound, Mounjaro |
| Abbott Laboratories | $68.81 | 2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Amulet |
| Regeneron Pharmaceuticals, INC. | $65.91 | 2024 | Evkeeza |
| Medtronic, INC. | $64.97 | 2025 | Corevalve Evolut R |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.08 | 2022-2025 | Jardiance |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $54.09 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $44.80 | 2023-2024 | Farxiga |
| Ionis Pharmaceuticals, INC. | $35.80 | 2025 | Tryngolza |
| Chiesi USA, INC. | $33.02 | 2024-2025 | Juxtapid |
| Atricure, INC. | $25.39 | 2025 | Atriclip Laa Exclusion System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.05 | 2022 | |
| Pfizer INC. | $17.57 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $15.74 | 2023 | Inpefa |
| Impulse Dynamics (USA) INC. | $14.89 | 2024 | Optimizer |
| E.R. Squibb & Sons, L.L.C. | $14.66 | 2021 | |
| Azurity Pharmaceuticals, INC. | $12.95 | 2023 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Shugg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.